<DOC>
	<DOCNO>NCT01224808</DOCNO>
	<brief_summary>The aim Von Willebrand Disease ( VWD ) therapy treat prevent bleed episode due abnormal platelet adhesion abnormal blood coagulation result low abnormal Von Willebrand Factor ( VWF ) and/or Factor VIII ( FVIII ) level . The long-term efficacy safety VWF/FVIII concentrate , Biostate , investigate child , adolescent , adult VWD treatment VWF product require prophylactic therapy , haemostatic control surgery , control non-surgical , spontaneous , traumatic bleeding event .</brief_summary>
	<brief_title>Extension Study Biostate Subjects With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Have complete Study CSLCTBIO0852 ( Assessment Efficacy Safety Biostate Paediatric Subjects Von Willebrand Disease ) Study CSLCTBIO0854 ( Assessment Efficacy Safety Biostate Adolescent Adult Subjects Von Willebrand Disease ) . The subject and/or his/her legal guardian understand ( ) nature study has/have give write informed consent participate study is/are willing comply protocol . Early discontinuation subject main study CSLCTBIO0852 CSLCTBIO0854 . Mental condition render subject ( subject 's legal guardian ) unable understand nature , scope possible consequence study . Any condition likely interfere evaluation IMP satisfactory conduct study . Are willing and/or able comply study requirement . Employee study site , spouse/partner relative Investigator Subinvestigators . Female subject childbearing potential either use , willing use , medically reliable method contraception entire duration study , sexually abstinent entire duration study , surgically sterile . Intention become pregnant course study . Pregnancy , nurse mother .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>von Willebrand Disease</keyword>
</DOC>